Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $95 | $225 | $72 | $171 |
| Short-Term Investments | $197 | $2 | $145 | $0 |
| Receivables | $48 | $18 | $4 | $0 |
| Inventory | $3 | $3 | $0 | $0 |
| Other Curr. Assets | $15 | $8 | $5 | $4 |
| Total Curr. Assets | $357 | $256 | $225 | $176 |
| Property Plant & Equip (Net) | $3 | $3 | $2 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $8 | $4 | $0 | $0 |
| Long-Term Investments | $3 | $1 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $6 | $2 | $1 | $1 |
| Total NC Assets | $20 | $9 | $2 | $3 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $377 | $265 | $228 | $179 |
| Liabilities | – | – | – | – |
| Payables | $28 | $18 | $5 | $3 |
| Short-Term Debt | $1 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $52 | $19 | $9 | $7 |
| Total Curr. Liab. | $81 | $37 | $15 | $11 |
| LT Debt | $72 | $30 | $19 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $2 | $0 | $0 |
| Total NC Liab. | $72 | $32 | $20 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $0 | $1 | $2 |
| Total Liabilities | $152 | $69 | $35 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$360 | -$245 | -$109 | -$47 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $585 | $442 | $302 | $213 |
| Total Equity | $225 | $197 | $193 | $167 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $377 | $265 | $228 | $179 |
| Net Debt | -$22 | -$195 | -$51 | -$169 |